FY2025 · ended Dec 31, 2025 · Revenue $431,609, +215.9% YoY · Filed Mar 30, 2026
Scienture Holdings, Inc. (SCNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $431,609 and a net loss of $41.5 million. As of Jun 30, 2026 it held $8.2 million in cash and investments and $2,546 in total debt.
Revenue (TTM)
$821,315
+540.6% vs year-ago TTM
Net income (TTM)
$-37.95M
-88.5% vs year-ago TTM
Operating cash flow (TTM)
$-14.44M
-8.7% vs year-ago TTM
Free cash flow
$-14.28M
-451.5% vs prior year
EPS (TTM)
$-1.31
+43.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
40.63M
+0.0% vs prior year
Net cash
$8.19M
as of Jun 30, 2026
Operating margin
-4878.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SCNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Commack, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1382574
- Former names
- TRxADE HEALTH, INC (until Aug 28, 2024); TRXADE GROUP, INC. (until May 28, 2021); XCELLINK INTERNATIONAL INC. (until Jan 31, 2014); Bluebird Exploration Co. (until Dec 10, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $431,609 | $136,643 | $1.4M | $10.3M | $9.9M |
| Operating income | -$42.6M | -$14.7M | -$4.4M | -$2.9M | -$5.3M |
| Net income | -$41.5M | $9.1M | -$17.8M | -$3.5M | -$5.3M |
| Diluted EPS | -$2.70 | $2.48 | -$23.35 | -$6.13 | — |
| Operating cash flow | -$13.4M | -$14.3M | — | -$1.5M | -$2.6M |
| Free cash flow | — | -$14.3M | — | — | -$2.6M |
| Total assets | $84.2M | $104.9M | $12.5M | $3.7M | $5.8M |
| Total liabilities | $14.1M | $25.8M | $12.0M | $3.4M | $2.0M |
| Stockholders' equity | $70.1M | $79.1M | $542,353 | $763,136 | $3.8M |
| Cash and investments | $6.7M | — | $151,908 | $1.1M | $3.1M |
| Total debt | $24,137 | $3.1M | $548,910 | $1.1M | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Nov 3, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations, Listing notice
|
Oct 19, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Oct 7, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 20, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 507 Scienture Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.